文献速递腹部MR

FAST、MAST与基于多参数MRI的新评分在诊断高危MASH中的头对头比较

Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score in diagnosing at-risk MASH.
PubMed 文献 · Eur Radiol · 2024-12-05

前瞻性研究纳入176例疑似或确诊MASLD患者,均行MR扫描、振动控制瞬时弹性成像和肝活检。基于MRE的LSM联合PDFF与cT1构建的两步策略M-PcT在诊断高危MASH时AUROC为0.832,高于FAST(0.744)、MAST(0.710)和MPcT(0.695),且遵循纳入标准时M-PcT阳性预测值为84.5%,高于FAST的73.5%、MAST的70.0%和MPcT的66.7%。

要点

  • 两步策略M-PcT诊断高危MASH的AUROC为0.832,高于FAST的0.744、MAST的0.710和MPcT的0.695。
  • 按纳入标准,M-PcT阳性预测值84.5%,高于FAST的73.5%、MAST的70.0%和MPcT的66.7%。
  • 按排除标准,M-PcT阴性预测值88.7%,高于FAST的84.0%、MAST的73.9%和MPcT的84.9%。

核心结论

  • 两步策略M-PcT(配对评分)对高危MASH的纳入和排除均显示可靠性,预测性能优于FAST和MAST(组合评分)。

研究设计与样本

  • 前瞻性研究,纳入176例疑似或确诊MASLD患者,均行MR扫描、振动控制瞬时弹性成像和肝活检;采用5折交叉验证评估诊断准确性;临床试验注册号UMIN000012757。

诊断标准与关键数值

  • 在高危MASH诊断中,M-PcT的AUROC为0.832,高于FAST的0.744(p=0.017)、MAST的0.710(p=0.002)和MPcT的0.695(p<0.001)。按纳入标准,M-PcT阳性预测值84.5%,高于FAST的73.5%、MAST的70.0%和MPcT的66.7%;按排除标准,M-PcT阴性预测值88.7%,高于FAST的84.0%、MAST的73.9%和MPcT的84.9%。

临床应用与阅片要点

  • 作者指出,通过联合MRE、PDFF与cT1,可在无需肝活检的情况下评估MASH病理,辅助预后预测和治疗方案决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: New scores were developed to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) using multiparametric MRI (mpMRI).

MATERIALS AND METHODS: A prospective study was conducted on 176 patients with suspected or diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) paired with an MR scan, vibration-controlled transient elastography (VCTE), and liver biopsy. Liver stiffness measurement (LSM) using magnetic resonance elastography (MRE), proton density fat fraction (PDFF), and mpMRI-based corrected T1 (cT1) were combined to develop a one-step strategy, named MPcT (MRE + PDFF + cT1, combined score), and a two-step strategy-MRE-based LSM followed by PDFF with cT1 (M-PcT, paired score) for diagnosing at-risk MASH. Each model was categorized using rule-in and rule-out criteria (three categorized analyses). To avoid overfitting, the diagnostic accuracies were evaluated based on 5-fold cross-validation.

RESULTS: PDFF + cT1 (PcT) had the highest diagnostic performance for severe activity (hepatic inflammation plus ballooning grade ≥ 3) and for NAS ≥ 4 (active MASH). Areas under receiver operating characteristic curves (AUROCs) of M-PcT (0.832) for detecting at-risk MASH were significantly higher than those of Fibroscan-AST (FAST) (0.744, p = 0.017), MRI-AST (MAST) (0.710, p = 0.002), and MPcT (0.695, p < 0.001) in three categorized analysis. Following the rule-in criteria, positive predictive values of M-PcT (84.5%) were higher than those of FAST (73.5%), MAST (70.0%), and MPcT (66.7%). Following the rule-out criteria, negative predictive values of M-PcT (88.7%) were higher than those of FAST (84.0%), MAST (73.9%), and MPcT (84.9%).

CONCLUSIONS: The two-step strategy, M-PcT (paired score), showed the reliability of rule-in/-out for at-risk MASH, with better predictive performance compared with FAST and MAST (combined score).

CLINICAL TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov (number, UMIN000012757).

KEY POINTS: Question There is no mpMRI-based method for detecting as-risk MASH (NAFLD activity score ≥ 4 with fibrosis stage ≥ 2) like FAST and MAST scores. Findings MRE-based LSMs followed by PDFF with cT1 (M-PcT) were more useful in detecting at-risk MASH than the combined score (FAST and MAST). Clinical relevance By combining MRE and PDFF with cT1, it becomes possible to evaluate the pathology of MASH without the need for a liver biopsy, assisting in prognosis prediction and decision-making for treatment options.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Imajo K, Saigusa Y, Kobayashi T, et al. Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score in diagnosing at-risk MASH. Eur Radiol. 2024. PMID: 39638942. doi:10.1007/s00330-024-11215-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。